利托那韦、奥比他韦、帕利瑞韦和达沙布韦在一名肾移植受者中的严重肝毒性。 - Suppr

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

作者信息

Bukal Nikolina, Furic-Cunko Vesna, Juric Ivana, Katalinic Lea, Dedo Antonia, Basic-Jukic Nikolina

机构信息

Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.

出版信息

Saudi J Kidney Dis Transpl. 2019 Sep-Oct;30(5):1184-1186. doi: 10.4103/1319-2442.270279.

DOI:10.4103/1319-2442.270279

PMID:31696862

Abstract

摘要

相似文献

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

Saudi J Kidney Dis Transpl. 2019 Sep-Oct;30(5):1184-1186. doi: 10.4103/1319-2442.270279.

Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):216, 219-20, 222. doi: 10.1331/JAPhA.2015.15512.

Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.

Exp Clin Transplant. 2019 Feb;17(1):52-58. doi: 10.6002/ect.2018.0095.

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.

Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x.

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb.

Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).

Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1073-1076. doi: 10.1097/MEG.0000000000001166.

Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.

J Clin Pharm Ther. 2017 Feb;42(1):115-118. doi: 10.1111/jcpt.12475. Epub 2016 Nov 3.

Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):9-13.

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.

Drugs. 2015 Jun;75(9):1027-38. doi: 10.1007/s40265-015-0412-z.

引用本文的文献

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking.

Pathogens. 2023 Jun 18;12(6):842. doi: 10.3390/pathogens12060842.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

作者信息

Bukal Nikolina, Furic-Cunko Vesna, Juric Ivana, Katalinic Lea, Dedo Antonia, Basic-Jukic Nikolina

机构信息

Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb and School of Medicine, University of Zagreb, Zagreb, Croatia.

出版信息

Saudi J Kidney Dis Transpl. 2019 Sep-Oct;30(5):1184-1186. doi: 10.4103/1319-2442.270279.

DOI:10.4103/1319-2442.270279

PMID:31696862

Abstract

摘要

相似文献

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

Saudi J Kidney Dis Transpl. 2019 Sep-Oct;30(5):1184-1186. doi: 10.4103/1319-2442.270279.

Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):216, 219-20, 222. doi: 10.1331/JAPhA.2015.15512.

Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.

Exp Clin Transplant. 2019 Feb;17(1):52-58. doi: 10.6002/ect.2018.0095.

Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10.

Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.

Clin Drug Investig. 2016 Aug;36(8):625-35. doi: 10.1007/s40261-016-0407-x.

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):855-61. doi: 10.1128/AAC.01913-15. Print 2016 Feb.

Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).

Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1073-1076. doi: 10.1097/MEG.0000000000001166.

Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.

J Clin Pharm Ther. 2017 Feb;42(1):115-118. doi: 10.1111/jcpt.12475. Epub 2016 Nov 3.

Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):9-13.

Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.

Drugs. 2015 Jun;75(9):1027-38. doi: 10.1007/s40265-015-0412-z.

引用本文的文献

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking.

Pathogens. 2023 Jun 18;12(6):842. doi: 10.3390/pathogens12060842.

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Severe hepatotoxicity of ritonavir, ombitasvir, paritaprevir, and dasabuvir in a kidney transplant recipient.

作者信息

机构信息

出版信息

相似文献

引用本文的文献